The IBN SINA Pharmaceutical Industry PLC (DSE:IBNSINA)
Bangladesh · Delayed Price · Currency is BDT 322.30
-1.60 (-0.49%)
At close: Jan 22, 2026
DSE:IBNSINA Revenue
The IBN SINA Pharmaceutical Industry had revenue of 3.72B BDT in the quarter ending September 30, 2025, with 34.86% growth. This brings the company's revenue in the last twelve months to 12.84B, up 14.36% year-over-year. In the fiscal year ending June 30, 2025, The IBN SINA Pharmaceutical Industry had annual revenue of 11.88B with 4.51% growth.
Revenue (ttm)
12.84B
Revenue Growth
+14.36%
P/S Ratio
0.78
Revenue / Employee
2.47M
Employees
5,200
Market Cap
10.07B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 11.88B | 512.67M | 4.51% |
| Jun 30, 2024 | 11.37B | 2.25B | 24.61% |
| Jun 30, 2023 | 9.13B | 645.51M | 7.61% |
| Jun 30, 2022 | 8.48B | 1.10B | 14.96% |
| Jun 30, 2021 | 7.38B | 1.18B | 19.13% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Beximco Pharmaceuticals PLC. | 46.34B |
| Renata | 44.03B |
| The ACME Laboratories | 37.48B |
| Beacon Pharmaceuticals | 11.58B |
| Navana Pharmaceuticals | 9.52B |
| Unilever Consumer Care | 3.63B |
| Techno Drugs | 3.23B |
| Orion Pharma | 3.23B |